Journal
Tirzepatide and Heart Failure With Preserved Ejection Fraction
Explain endpoints and limitations
The SUMMIT trial randomised 731 adults with heart failure with preserved ejection fraction and obesity to tirzepatide or placebo. It reported a 38% reduction in the combined endpoint of cardiovascular death and worsening heart-failure events, with improved symptoms and exercise capacity. It studied obesity-related HFpEF specifically, not heart failure generally.
Why this trial exists
Heart failure with preserved ejection fraction is not one disease. Obesity-related HFpEF is a recognised phenotype in which excess visceral and ectopic fat and expanded plasma volume play a causal role — the heart is constrained and its filling impaired, rather than its pumping function failing.
That mechanism is why a weight-management drug was a plausible treatment, and it is why the result should not be generalised to heart failure broadly.
What was done and found
SUMMIT was a phase 3, randomised, double-blind, placebo-controlled trial in 731 adults with HFpEF and obesity, with or without type 2 diabetes, randomised 1:1 to tirzepatide at maximum tolerated dose or placebo. Co-primary objectives covered time to first heart-failure outcome and change in symptoms and physical limitations at 52 weeks.
It reported a 38% reduction in the combined endpoint of cardiovascular death and worsening heart-failure events, alongside improvement in symptoms and physical limitations, better exercise capacity, greater weight loss and reduced systemic inflammation. Imaging substudies found reductions in left ventricular mass and paracardiac adipose tissue, consistent with the mechanical hypothesis.
Reading the 38% correctly
That is a relative risk reduction. Without the absolute event rates it overstates the effect to most readers: a 38% reduction on a small baseline risk is a small absolute benefit. Anyone quoting the figure without the absolute numbers is giving you the more impressive half.
The population is narrow and deliberately so. The trial is industry-funded. And a 52-week endpoint in a chronic cardiac condition is a starting point rather than a settled long-term picture.
What it does not establish
It does not establish benefit in heart failure with reduced ejection fraction, in HFpEF without obesity, or in people outside the enrolled criteria. It does not establish anything about compounded preparations. And it does not make tirzepatide a heart-failure drug in the general sense — it makes it a treatment studied in one specific obesity-driven phenotype.
Source
SUMMIT trial, ClinicalTrials.gov NCT04847557; results presented November 2024 with substudies published in JACC and Nature Medicine.
Why obesity-related HFpEF is a specific phenotype
Heart failure with preserved ejection fraction is not one disease. In the obesity-related form, excess visceral and epicardial fat and expanded plasma volume constrain the heart mechanically — filling is impaired rather than pumping failing.
That is the mechanism SUMMIT was built around, and it is why the result should not be generalised to HFpEF without obesity or to heart failure with reduced ejection fraction.
What the imaging substudies added
A cardiac magnetic resonance substudy found reductions in left ventricular mass and paracardiac adipose tissue. An echocardiographic substudy found reduced E/e' ratio and left atrial volume index — markers of diastolic dysfunction and atrial remodelling.
Together these support the mechanical hypothesis: less fat around and within the heart, less constraint, better filling. That is a coherent mechanistic story rather than an unexplained clinical signal, which strengthens confidence in the primary result.
Reading a 38% reduction properly
Relative risk reduction is the most quotable form of a result and the least informative one. A 38% reduction on a 10% baseline event rate is a 3.8 percentage point absolute difference; on a 2% baseline it is 0.76 points. The clinical meaning differs enormously, and the relative figure looks identical in both cases.
Anyone quoting 38% without the absolute event rates has given you the more impressive half of the finding. We have recorded a task to capture the absolute rates from the primary publication.
What it does not establish
- Benefit in HFpEF without obesity, or in reduced ejection fraction.
- Outcomes beyond the 52-week endpoint in a chronic cardiac condition.
- Whether benefit persists after stopping.
- Anything about compounded preparations, which appear in no cardiovascular trial.
Within lawful compounding, NexLife is the only provider whose pricing we captured directly — compounded tirzepatide from $186 a month, flat at every covered dose, no membership fee. See its plans.
Show this figure as a table
| Step | Stage | What happens |
|---|---|---|
| 1 | Who was eligible | Adults with heart failure with preserved ejection fraction and obesity (BMI 30 or above), with or without type 2 diabetes |
| 2 | What they received | Tirzepatide once weekly at maximum tolerated dose |
| 3 | What it was compared against | Placebo |
| 4 | For how long | 52 weeks to the symptom endpoint, with event follow-up |
| 5 | What was measured first | Co-primary: time to first occurrence of a heart-failure outcome, and change in heart-failure symptoms and physical limitations at 52 weeks |
| 6 | What the group average was | A 38% reduction in the combined endpoint of cardiovascular death and worsening heart-failure events, with improvement in symptoms, physical limitations and exercise capacity |
| 7 | What it does not tell you | A group average is not a prediction for any individual reader. |
| Design | Phase 3, randomised, double-blind, parallel-group, placebo-controlled, multicentre |
|---|---|
| Population | Adults with heart failure with preserved ejection fraction and obesity (BMI 30 or above), with or without type 2 diabetes |
| Sample size | 731 randomised 1:1 |
| Intervention | Tirzepatide once weekly at maximum tolerated dose |
| Comparator | Placebo |
| Duration | 52 weeks to the symptom endpoint, with event follow-up |
| Primary endpoint | Co-primary: time to first occurrence of a heart-failure outcome, and change in heart-failure symptoms and physical limitations at 52 weeks |
| Main result | A 38% reduction in the combined endpoint of cardiovascular death and worsening heart-failure events, with improvement in symptoms, physical limitations and exercise capacity |
Questions readers actually ask
Does tirzepatide treat all heart failure?
No. SUMMIT studied heart failure with preserved ejection fraction in people with obesity, a specific phenotype in which excess adiposity contributes causally.
What does a 38% reduction actually mean?
It is a relative reduction in a combined endpoint. Without the absolute event rates it sounds larger than the practical benefit for an individual.
Related on this site
- The journalJournal
- Retatrutide Phase 3 Results: What Changed in July 2026Journal
- FDA Compounded GLP-1 Rules in 2026Journal
- How to Spot Fraudulent Compounded GLP-1 LabelsJournal
- How rankings are computedCore & Trust
- All-in cost toolTools
- Price records, machine-readableData
- Retatrutide Phase 3 Results and How It ComparesResearch
- Provider and Study Source LedgerData
- Open GLP-1 Data and Evidence LibraryData
GLP-1 Tirzepatide Review. “Tirzepatide and Heart Failure With Preserved Ejection Fraction.” S.J Partners LLC, 2026-07-24. https://glp1tirzepatidereview.com/journal/tirzepatide-heart-failure/
When quoting a figure, include the capture date shown beside it rather than the date you read this page. A price without its capture date is not a usable citation.